Membrane-protecting therapies for neurodegenerative diseases
Our therapy areas
Protein misfolding diseases
Disease | Associated protein/peptide | Symptomatic treatments | Disease-modifying treatments |
Parkinson's disease (PD) | α-Synuclein (αSyn) | Levodopa with carbidopa, COMT inhibitors, dopamine agonists, MAO inhibitors, melatonin, clonazepam, acetylcholinesterase inhibitors | None |
Alzheimer's disease (AD)
Hereditary cerebral haemorrhage with amyloidosis (HCHWA)
Cerebral amyloid angiopathy (CAA)
Inclusion body myositis (IBM)
Retinal degeneration (glaucoma)
Macular degeneration (AMD) | β-amyloid peptide (Aβ)
Tau protein (Tau) | Acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine donepezil), memantine | None - Lecanemab is approved by FDA |
Amyotrophic lateral sclerosis (ALS) | |||
Alzheimer's disease (AD)
Hereditary cerebral haemorrhage with amyloidosis (HCHWA)
Cerebral amyloid angiopathy (CAA)
Inclusion body myositis (IBM)
Retinal degeneration (glaucoma)
Macular degeneration (AMD) | β-amyloid peptide (Aβ)
Tau protein (Tau) | Acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine donepezil), memantine | None - Lecanemab is approved by FDA |
Amyotrophic lateral sclerosis (ALS) | TAR DNA-binding protein 43 (TDP-43), Fused in sarcoma (FUS), Ubiquilin-2 (UBQLN2), Superoxide dismutase (SOD1) | Riluzole, edaravone, selective serotonin reuptake inhibitors (SSRIs), cholinesterase inhibitors, antipsychotics | None |
Huntington's disease (HD)
Other CAG repeat disorders:
Spinal and bulbar muscular atrophy
Spinocerebellar ataxia (SCA1, etc.)
Dentatorubropallidoluysian atrophy | Huntingtin (HTT)
Other polyglutamine-containing proteins: Androgen receptor (AR), Ataxin-1, 2, 3, Atrophin-1 (ATN1) | Tetrabenazine, benzodiazepines, valproic acid, antipsychotics | None |
Other synucleinopathies:
Parkinson's disease dementia (PDD)Dementia with Lewy bodies (DLB)Multiple system atrophy (MSA)REM sleep behavior disorder (RBD)
| |||
Other β-amyloid pathologies:
Hereditary cerebral haemorrhage with amyloidosis (HCHWA)
Cerebral amyloid angiopathy (CAA)
Inclusion body myositis (IBM)
Retinal degeneration (glaucoma)
Macular degeneration (AMD) | β-amyloid peptide (Aβ) | Antihypertensives, corticosteroids, anticonvulsants | None |
Other tauopathies:
Chron. traum. encephalopathy (CTE)Progressive supranuclear palsy (PSP)
Corticobasal degeneration (CBD)
Argyrophilic grain disease (AGD) | Tau protein (Tau) | Selective serotonin reuptake inhibitors (SSRIs), antipsychotics, acetylcholinesterase inhibitors, levodopa, amantadine, ropinirole, clonazepam, memantine | None |
Frontotemporal dementia (FTD)
Other forms of frontotemporal lobar degeneration (FTLD):
Semantic dementia (SD) | Tau protein (Tau), TAR DNA-binding protein (TDP-43), Fused in sarcoma protein (FUS) | Selective serotonin reuptake inhibitors (SSRIs), antipsychotics, acetylcholinesterase inhibitors | None |
Type II diabetes (T2D) | Islet amyloid polypeptide (IAPP) | Metformin, thiazolidinediones, sulfonylureas, SGLT2 inhibitors, insulin and insulin analogs | None |
Creutzfeldt-Jacob disease (CJD)Other prion diseases: Gerstmann–Sträussler–Scheinker syndrome (GSS); Fatal familial insomnia (FFI) | Prion protein (PrP) | None | None |
Senile systemic amyloidosis (SSA)
Other transthyretin pathologies:
Hered. transthyretin amyloidosis
Fam. amyloid polyneuropathy (FAP)
Fam. amyloid cardiomyopathy (FAC) | Transthyretin (TTR) | Tafamidis (EU only), diflunisal | Patisiran (siRNA therapy)
Inotersen (antisense therapy) |
I’m a paragraph. Drag me to add paragraph to your block, write your own text and edit me.